Many people among us contend with unknown-to-us dreadful conditions. Periodically in this newsletter, we highlight new research that could lead to a truly better life for some of our neighbors.<\/p>\n
One such challenge is hereditary angioedema<\/i> (HAE) \u2013 a genetically inherited disorder that leads to severe, and sometimes life-threatening, swelling throughout the body. Often-affected areas are the extremities, gut, face and airway. A deficiency of the protein C-1-esterase inhibitor <\/i>is the culprit. Lack of this protein allows a build-up of kallikrein, kininogen and bradykinin, causing the tissue swelling.<\/p>\n
Fairly early-stage research reported recently in the New England Journal of Medicine<\/i> into the use of Lanadelumab in treating HAE revealed startling positive results. These monoclonal antibodies removed kallikrein through bi-weekly administration by subcutaneous injection. The result showed almost complete cessation of the swelling attacks.<\/p>\n
Additional studies will be required before the FDA approval can be forthcoming, but if use of Lanadelumab proves to be safe, it will be a major improvement in preventive therapy for HAE.<\/p>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Many people among us contend with unknown-to-us dreadful conditions. Periodically in this newsletter, we highlight new research that could lead to a truly better life for some of our neighbors. One such challenge is hereditary angioedema (HAE) \u2013 a genetically inherited disorder that leads to severe, and sometimes life-threatening, swelling throughout the body. Often-affected areas are the extremities, gut, face and airway. A deficiency of the protein C-1-esterase inhibitor is the culprit. Lack of this protein allows a build-up of…<\/p>\n